How do pediatric glycogen storage disorder nurses explain to Spanish-speaking parents why GSD type I requires overnight cornstarch at three-hour intervals when the child's bedtime glucose appears normal and the child shows no symptoms of hypoglycemia?

The explanation requires establishing what the normal bedtime glucose represents and what it does not represent. Glycogen storage disease type I is caused by biallelic mutations in the G6PC gene (GSD Ia) or SLC37A4 gene (GSD Ib) that prevent the synthesis of functional glucose-6-phosphatase, the enzyme located in the endoplasmic reticulum membrane of hepatocytes that dephosphorylates glucose-6-phosphate to free glucose. Glucose-6-phosphate is the final common intermediate of two distinct hepatic glucose-producing pathways: glycogenolysis (glycogen → glucose-1-phosphate → glucose-6-phosphate) and gluconeogenesis (amino acids, lactate, and glycerol → pyruvate → oxaloacetate → phosphoenolpyruvate → glucose-6-phosphate). Both pathways produce glucose-6-phosphate, and both require glucose-6-phosphatase to export free glucose across the endoplasmic reticulum membrane and into the hepatic portal circulation. Without glucose-6-phosphatase, neither glycogenolysis nor gluconeogenesis can release glucose from the liver into the bloodstream. The liver in GSD type I children contains enormous quantities of glycogen — accumulating because glucose-6-phosphate cannot be converted to glucose and instead drives glycogen synthesis, glycolysis to pyruvate, and conversion of pyruvate to lactate and fatty acids (producing the secondary lactic acidosis and hyperlipidemia characteristic of GSD I). The glycogen is visible on liver ultrasound as dense echogenicity. But it is metabolically trapped. The liver cannot release a single glucose molecule from its glycogen stores without glucose-6-phosphatase. The normal bedtime glucose reading of 92 mg/dL, 88 mg/dL, or whatever value the monitor shows at bedtime is the direct product of glucose absorbed from the most recent cornstarch dose. Uncooked cornstarch (UCCS) contains raw granular starch that is digested slowly by pancreatic amylase over approximately three to six hours — much more slowly than cooked starch or simple sugars — providing a sustained low-level glucose infusion from the gastrointestinal tract. When parents observe a normal bedtime glucose, they are observing the tail end of that absorption curve. There is no hepatic reserve behind that number. When cornstarch absorption is complete — typically two to four hours after the last oral dose, or as early as two hours after the last continuous gastrostomy tube feed if the pump is disconnected — blood glucose begins falling. In a child without GSD, glucose begins falling, the liver responds by releasing glucose from glycogen (glycogenolysis) within minutes and from gluconeogenesis within hours. That response does not exist in GSD type I. Glucose continues falling without interruption. Children with GSD type I develop profound hypoglycemia — glucose below 40 mg/dL in two to four hours, below 25 mg/dL in six to eight hours — following interruption of exogenous carbohydrate. The additional complication that makes overnight hypoglycemia specifically dangerous is chronic hypoglycemia adaptation. GSD type I children who have experienced repeated hypoglycemia develop blunted adrenergic responses: the epinephrine surge that produces sweating, shakiness, pallor, and hunger in a non-GSD child at glucose 60 mg/dL is markedly attenuated in GSD I children. These children can be deeply hypoglycemic — glucose 20, 14, even lower — without showing any behavioral signs of distress. The parents do not hear crying. The child does not wake. The child may not show visible symptoms until glucose is at a level that causes brain injury. This is why the overnight cornstarch or gastrostomy tube continuous feed is not adjustable based on how the child appears — appearance is not a reliable indicator of glucose status in a GSD type I child.

How do pediatric glycogen storage disorder nurses explain to Spanish-speaking parents why GSD type IIIa requires high dietary protein when they expected protein restriction for liver disease and the child has never had a hypoglycemic episode?

The explanation requires separating the dietary logic of GSD type III from the dietary logic of the liver diseases families have encountered or researched online, and explaining why muscle disease — not hepatic disease — is driving the protein recommendation. Glycogen storage disease type III (Cori disease) is caused by biallelic mutations in the AGL gene encoding the glycogen debranching enzyme, which has two catalytic activities on the same polypeptide: a transferase that moves three glucose units from a branch chain to the main chain, and a glucosidase that cleaves the single remaining branch-point glucose. Without the debranching enzyme, glycogen can be partially mobilized from linear chain segments by glycogen phosphorylase — which is why GSD type III produces milder fasting hypoglycemia than GSD type I, and why many GSD III children have no hypoglycemic episodes after the first few years of life as their gluconeogenic capacity matures. However, each cycle of glycogen mobilization via phosphorylase deposits the branch-point glucose residues as incompletely degraded glycogen (limit dextrin) that cannot be cleared and accumulates in the liver and in skeletal muscle. The GSD IIIa subtype, comprising approximately 85% of GSD III cases, affects both liver and muscle (AGL mutations that inactivate both enzyme activities, or that inactivate the glucosidase activity selectively). GSD IIIb affects liver only. The distinction matters because in GSD IIIa the muscle debranching enzyme absence drives a disease process independent of hepatic disease, and it is more serious in the long run. Skeletal muscle glycogen accumulation in GSD IIIa produces progressive myopathy that typically becomes more symptomatic with age: proximal muscle weakness, exercise intolerance, and elevated creatine kinase. The creatine kinase elevation in GSD IIIa children — often in the range of 1,000 to 5,000 U/L — reflects ongoing skeletal muscle cell membrane damage from glycogen accumulation and the mechanical stress it places on contracting muscle fibers. This process begins in childhood and is already measurable by the time of diagnosis even when children do not yet have clinical weakness. Cardiac muscle is also affected in GSD IIIa: glycogen accumulates in cardiomyocytes producing progressive left ventricular hypertrophy that can advance to hypertrophic cardiomyopathy with diastolic dysfunction and arrhythmias. Cardiomyopathy occurs in approximately 30% of GSD IIIa patients over time, and early echocardiographic changes — increased LV wall thickness — can be detected before symptoms in children. A child presenting with hepatomegaly and liver enzyme elevation (the typical pediatric GSD III presentation) who has early LV wall thickening on echocardiogram is already showing the cardiac signal of the process that will determine long-term outcomes. Dietary protein recommendation in GSD IIIa serves two distinct purposes. First, gluconeogenic substrate bypass: the hepatic gluconeogenic pathway (amino acids → pyruvate → oxaloacetate → glucose) does not require the debranching enzyme. Alanine and glutamine can be converted to glucose via pyruvate carboxylase and PEPCK without passing through any glycogen mobilization step. High dietary protein, particularly from lean animal sources, provides a continuous supply of gluconeogenic amino acids that bypass the debranching enzyme block, providing hepatic glucose output independent of glycogen. This is why children with GSD III who are past the most hypoglycemia-vulnerable early years can still benefit from protein as a metabolic stabilizer. Second, muscle protein synthesis substrate: the skeletal and cardiac muscle in GSD IIIa is under continuous catabolic pressure from glycogen-driven structural damage. Providing 3 to 4 g/kg/day of dietary protein — compared to the 1 to 2 g/kg/day recommended in urea cycle disorders or hepatic failure where the liver cannot process ammonia — gives the muscle cells the amino acid substrate needed for repair and maintenance of muscle protein. Reducing dietary protein in GSD IIIa, as families sometimes do after researching 'liver disease diet,' removes the only available substrate for muscle repair against ongoing glycogen-driven damage. The recommendation is the nutritional opposite of what families expect because the disease is the nutritional opposite of the liver diseases where protein restriction was developed.

How do pediatric glycogen storage disorder nurses explain to Spanish-speaking parents why McArdle disease is treated with a supervised aerobic exercise program when exercise episodes caused muscle breakdown and dark urine?

The explanation requires distinguishing between the type of exercise that caused the rhabdomyolysis episodes and the type of exercise that constitutes the treatment, and explaining why physical deconditioning makes McArdle disease worse rather than safer. Glycogen storage disease type V (McArdle disease) is caused by biallelic mutations in the PYGM gene encoding myophosphorylase, the muscle-specific isozyme of glycogen phosphorylase. Myophosphorylase in skeletal muscle performs the same function that glycogen phosphorylase performs in liver — releasing glucose-1-phosphate from glycogen for local glycolytic energy production — but it does so specifically within skeletal muscle fibers for their own immediate energy needs during exercise. Without myophosphorylase, skeletal muscle cannot access its own glycogen stores. Under resting conditions and during very light activity, skeletal muscle meets its energy needs primarily through circulating blood glucose and free fatty acids — oxidative metabolism via the mitochondria — and myophosphorylase absence is not limiting because glycogen is not required. The problem arises at higher exercise intensities. When exercise intensity increases beyond what blood glucose and fatty acid oxidation can supply, skeletal muscle normally supplements its energy needs with glycolytic energy from intramuscular glycogen. In McArdle disease, this supplement is unavailable. The muscle reaches a glycogen-limited energy crisis: ATP falls, AMP accumulates, the purine nucleotide cycle produces ammonia, and the membrane integrity of muscle fibers compromised by energy deficit breaks down — releasing myoglobin, creatine kinase, and other intracellular contents. Myoglobinuria (dark urine) reflects myoglobin — a heme protein — being filtered by kidneys after leaking from disrupted muscle cells. In high-intensity episodes, the cascade is rapid: a sprint, an explosive soccer kick, a maximal isometric effort, a steep stair climb at full pace — any effort that suddenly demands glycolytic energy supplementation produces muscle ischemia and rhabdomyolysis. The rhabdomyolysis episodes that diagnosed Diego occurred during high-intensity soccer practice — sprint intervals, explosive dueling, extended anaerobic effort. This is the critical distinction: the problem is not exercise in general. The problem is exercise intensity above the threshold at which muscle glycogen becomes required. The second wind phenomenon, which is pathognomonic of McArdle disease, demonstrates this distinction. At the onset of moderate aerobic exercise — walking briskly, cycling at moderate pace — patients with McArdle disease experience unusually high heart rates, fatigue, and muscle pain that is disproportionate to the actual effort. This reflects the early exercise period when muscle fibers are attempting to use glycogenolysis to supplement energy but cannot. Approximately 8 to 10 minutes into moderate aerobic exercise, something shifts: heart rate normalizes, muscle pain decreases, exercise becomes comfortable. This is the second wind — the physiological shift from reliance on intramuscular glycogen to reliance on circulating fatty acids as the primary oxidative fuel for slow-twitch muscle fibers. Fatty acid oxidation can sustain moderate aerobic exercise without requiring myophosphorylase. After the second wind, moderate aerobic exercise in McArdle disease is physiologically accessible and does not produce rhabdomyolysis. The supervised aerobic exercise program prescribed after McArdle diagnosis works by building oxidative capacity in slow-twitch muscle fibers: increasing mitochondrial density, increasing the density of oxidative enzymes, increasing the capacity to use circulating fatty acids and blood glucose as aerobic fuel. This raises the exercise intensity ceiling at which muscle glycogen would become required, effectively shifting the threshold upward. Physical deconditioning — the consequence of complete rest — does the opposite. A deconditioned muscle has fewer mitochondria, lower oxidative enzyme density, and lower capacity for fatty acid oxidation. In a deconditioned McArdle patient, the exercise intensity threshold at which glycogen becomes limiting falls. This means that activities the patient could previously do post-second-wind without rhabdomyolysis — a moderate walk, climbing stairs at normal pace, recreational activity — begin producing symptoms as oxidative capacity falls. The parents' instinct to enforce complete rest, while understandable, was progressively removing the physiological buffer that protects against the type of exercise crisis they were trying to prevent.

What are the key clinical Spanish phrases for explaining glycogen storage disorder management including overnight cornstarch timing, dietary protein recommendations, and exercise prescriptions to Spanish-speaking families in the pediatric GSD clinic?

Key clinical Spanish phrases for the pediatric glycogen storage disorder outpatient clinic, organized by the three communication challenges. For explaining GSD type I overnight cornstarch necessity: 'El glucómetro mostraba 92 mg/dL cuando Andrés se durmió porque la maicena que le dimos a las nueve de la noche todavía estaba siendo absorbida. No reflejaba la reserva de glucosa del hígado — reflejaba la glucosa de la maicena. El hígado de Andrés tiene abundante glucógeno — lo pueden ver en el ultrasonido como un tejido más denso. Pero ese glucógeno está atrapado. Para convertirlo en glucosa y mandarlo a la sangre, el hígado necesita una enzima llamada glucosa-6-fosfatasa. La mutación de Andrés impide que el hígado produzca esa enzima permanentemente. Cuando la maicena se termina de absorber — unas dos a cuatro horas después de la última dosis — la glucosa empieza a bajar y el hígado no puede hacer nada para detenerlo. No hay alarma. Andrés no va a despertar porque también tiene la adaptación del cuerpo a la hipoglucemia crónica — los síntomas que tendría un niño normal a glucosa 60 mg/dL, Andrés los puede no tener a glucosa 20 mg/dL. El tubo gástrico con la bomba de maicena no es precaución extra — es la única fuente de glucosa que Andrés tiene mientras duerme.' (The glucometer showed 92 mg/dL when Andrés fell asleep because the cornstarch we gave him at nine at night was still being absorbed. It did not reflect the liver's glucose reserve — it reflected the glucose from the cornstarch. Andrés's liver has abundant glycogen — you can see it on the ultrasound as a denser tissue. But that glycogen is trapped. To convert it to glucose and send it to the bloodstream, the liver needs an enzyme called glucose-6-phosphatase. Andrés's mutation permanently prevents the liver from producing that enzyme. When the cornstarch finishes being absorbed — roughly two to four hours after the last dose — glucose begins falling and the liver cannot do anything to stop it. There is no alarm. Andrés will not wake up because he also has the body's adaptation to chronic hypoglycemia — the symptoms a normal child would have at glucose 60 mg/dL, Andrés may not have at glucose 20 mg/dL. The gastrostomy tube with the cornstarch pump is not extra precaution — it is the only source of glucose Andrés has while sleeping.) For explaining GSD type IIIa high protein recommendation: 'La restricción de proteína es para enfermedades donde el hígado no puede procesar el amoníaco que produce la proteína — como los trastornos del ciclo de la urea. La enfermedad de Camila es diferente. En la MPS de tipo III, la enzima que falta está también en el músculo — en el músculo del esqueleto y en el músculo del corazón. Sin esa enzima, el glucógeno se va acumulando en las fibras musculares. El CK elevado de Camila — 1,680 — nos dice que las membranas de las células musculares están tomando daño de esa acumulación. El ecocardiograma muestra que las paredes del ventrículo izquierdo son un poco más gruesas de lo que deberían ser para el tamaño de Camila — eso es el glucógeno empezando a acumularse en el músculo cardíaco. La proteína alta en la dieta le da al hígado de Camila aminoácidos gluconeogénicos — alanina, glutamina — que se pueden convertir en glucosa sin necesitar la enzima que falta. Y le da al músculo el material de construcción que necesita para reparar el daño que el glucógeno acumulado está causando. Reducir la proteína quitaría ese material de reparación del músculo que más lo necesita.' (Protein restriction is for diseases where the liver cannot process the ammonia that protein produces — such as urea cycle disorders. Camila's disease is different. In GSD type III, the missing enzyme is also in the muscle — in skeletal muscle and in cardiac muscle. Without that enzyme, glycogen accumulates in muscle fibers. Camila's elevated CK — 1,680 — tells us that muscle cell membranes are sustaining damage from that accumulation. The echocardiogram shows that the left ventricular walls are a bit thicker than they should be for Camila's size — that is glycogen beginning to accumulate in cardiac muscle. High dietary protein gives Camila's liver gluconeogenic amino acids — alanine, glutamine — that can be converted to glucose without needing the missing enzyme. And it gives muscle the building material it needs to repair the damage that accumulated glycogen is causing. Reducing protein would remove that repair material from the muscle that needs it most.) For explaining McArdle disease aerobic exercise prescription: 'Los episodios de orina oscura de Diego ocurrieron durante esfuerzo de alta intensidad — los sprints y los duelos explosivos del entrenamiento de fútbol. En ese tipo de esfuerzo, el músculo necesita energía muy rápido, más de lo que el azúcar en sangre y las grasas pueden dar a tiempo. Normalmente el músculo complementa con el glucógeno muscular. Diego no tiene la enzima para hacer eso — la miofosforilasa no la produce su cuerpo y no puede producirla. Entonces en los esfuerzos de alta intensidad, el músculo tiene una crisis de energía y las membranas celulares se rompen. Eso es la mioglobinuria. El ejercicio aeróbico moderado es diferente. Cuando Diego camina a buen paso, o monta bicicleta a ritmo moderado, el músculo usa principalmente el azúcar en sangre y las grasas como combustible — y eso sí puede hacerlo, porque esas vías no necesitan la miofosforilasa. Al minuto ocho o diez de ejercicio moderado, Diego va a sentir que se hace más fácil — que el corazón se calma, que el músculo duele menos. A eso le llamamos el segundo aire. Ese es el momento en que las grasas en sangre se convierten en el combustible principal y Diego puede continuar. El programa de ejercicio aeróbico entrena las fibras musculares para usar más oxígeno y más grasa como combustible, que sube el nivel de intensidad al que el glucógeno muscular haría falta. Sin ejercicio, ese nivel baja — y las actividades que Diego podría hacer después del segundo aire se vuelven peligrosas porque el músculo pierde la capacidad aeróbica que lo protege.' (Diego's dark urine episodes occurred during high-intensity effort — the sprints and explosive duels of soccer training. In that type of effort, muscle needs energy very quickly, more than blood sugar and fats can deliver in time. Normally muscle supplements with muscle glycogen. Diego does not have the enzyme to do that — myophosphorylase is not produced by his body and cannot be produced. So during high-intensity efforts, the muscle has an energy crisis and cell membranes break down. That is the myoglobinuria. Moderate aerobic exercise is different. When Diego walks at a good pace, or cycles at moderate pace, the muscle uses primarily blood sugar and fats as fuel — and that he can do, because those pathways do not need myophosphorylase. At minute eight or ten of moderate exercise, Diego will feel it gets easier — that the heart calms, that the muscle hurts less. We call that the second wind. That is the moment when blood fats become the main fuel and Diego can continue. The aerobic exercise program trains muscle fibers to use more oxygen and more fat as fuel, which raises the intensity level at which muscle glycogen would be needed. Without exercise, that level falls — and activities Diego could do after the second wind become dangerous because the muscle loses the aerobic capacity that protects it.)

What are the most important communication challenges specific to Spanish-speaking families in the pediatric glycogen storage disorders outpatient clinic that standard translated handouts do not address?

Three structural communication challenges arise across the glycogen storage disorder subtypes and are inadequately addressed by translated handouts. The first is the normal-glucose paradox in GSD type I. Families of GSD type I children who have been managing the disease for several years typically achieve consistently normal glucometer readings by following the cornstarch regimen precisely. The very success of the regimen creates the misunderstanding: normal glucose readings are interpreted as evidence that the glucose-regulating system is working, rather than as evidence that the external cornstarch supply is working. The written handout requiring overnight cornstarch every three to four hours states the requirement without explaining what produces the number on the glucometer. The critical concept that families cannot have without explanation is that the liver in GSD type I is not a participant in glucose regulation. It contains glycogen but cannot release it. Every normal glucose reading after diagnosis reflects an external carbohydrate source — no exceptions. When families understand that the glucose reading and the hepatic reserve are disconnected, the logic of the overnight dosing becomes self-evident: there is no hepatic reserve to fall back on if the cornstarch lapses. The additionally dangerous feature of GSD type I hypoglycemia — the attenuation of adrenergic symptoms from chronic exposure — means the child cannot be relied upon to signal distress. The parents are the glucose monitoring system, and the overnight pump is the glucose delivery system. There is no redundancy. The second challenge is explaining that GSD type IIIa is two simultaneous diseases in the same patient. The hepatic disease — hepatomegaly, transaminase elevation, fasting hypoglycemia in early childhood — is what brings the patient to diagnosis and is what the family monitors with laboratory tests. This disease does improve with age and dietary management. The muscle disease — skeletal and cardiac myopathy from glycogen accumulation in AGL-deficient muscle fibers — does not track hepatic disease activity, does not respond to the same dietary interventions in the same way, and can progress while hepatic markers normalize. Families who monitor their child's liver function and see improvement over years can develop a model in which the disease is getting better overall, which is partially correct but misses the silent progressive component. The cardiomyopathy risk in GSD IIIa — affecting approximately 30% of patients with the hepatic-plus-muscle subtype — is particularly important to communicate because it is the most serious long-term complication, it can appear as early adolescence, and it is detectable by echocardiographic wall thickness before symptoms. A family that understands they have a child with two diseases — one that is improving, one that requires continuous dietary support and cardiac surveillance — is a family that maintains the protein intake and cardiology appointments that protect against the disease the lab does not show. The third challenge is reversing the instinctive treatment logic for McArdle disease. In every other context parents have encountered, a child who had muscle breakdown after exercise is told to rest — rest is the treatment for muscle injury, rest is what athletes do after overtraining, rest is what doctors recommend after a myoglobinuria episode during the acute recovery period. The McArdle disease management recommendation — supervised aerobic exercise as the long-term treatment — contradicts this logic and requires an explanation that the families' prior experience cannot supply. The key that unlocks the explanation is the second wind phenomenon. The second wind is not a metaphor — it is a measurable physiological event in McArdle disease that families can observe, predict, and use. When a family understands that their child's muscle is perfectly capable of using blood glucose and fatty acids as aerobic fuel, that the second wind marks the transition to that fuel source, and that the aerobic exercise program is building the oxidative capacity that makes the transition easier and the post-second-wind exercise zone wider, the exercise prescription becomes logical rather than alarming. When families also understand that deconditioning narrows this protective zone — that the child they are protecting by enforcing rest is becoming progressively more vulnerable to rhabdomyolysis from any physical effort — the urgency of the supervised aerobic program becomes something the family can act on with understanding rather than compliance.

Spanish for pediatric glycogen storage disorders clinic nurses — the parents who cannot understand why uncooked cornstarch must be given at three-hour intervals through the night when their son with GSD type I had a bedtime glucose of 92 mg/dL not knowing G6Pase is permanently absent and the liver cannot release any stored glucose making the normal bedtime reading the direct product of the last dose while six hours without cornstarch drops glucose to 14 mg/dL silently; the parents who cannot understand why their daughter with GSD type IIIa is being told to increase dietary protein when they expected restriction from liver disease not knowing the muscle debranching enzyme deficiency is silently causing cardiomyopathy and skeletal myopathy requiring protein as gluconeogenic substrate and muscle repair material independent of hepatic disease; and the parents who cannot understand why their son with McArdle disease is being prescribed a supervised aerobic exercise program when exercise caused the muscle breakdown and dark urine episodes not knowing myophosphorylase is permanently absent so aerobic training builds the oxidative capacity that bypasses the glycogen block while deconditioning removes it

Pediatric glycogen storage disorder nursing requires explaining three management decisions that each appear to contradict the family’s direct experience. A six-year-old whose glucose meter shows 92 mg/dL at bedtime — a number that any parent would interpret as reassuring — whose overnight cornstarch gastrostomy tube feed the parents disconnected to give him a comfortable night’s sleep, and who was found unresponsive at 5 AM with glucose 14 mg/dL requiring an emergency 911 call. A ten-year-old whose hepatic disease markers are genuinely improving — transaminases trending down, hepatomegaly receding, no hypoglycemic episodes in two years — whose parents researched “liver disease diet” online, found protein restriction is the standard hepatic management, and cannot understand why their dietitian is recommending they increase their daughter’s protein intake to 3.5 g/kg per day. And a sixteen-year-old who experienced two frightening episodes of myoglobinuria after soccer practice, whose parents enforced complete physical rest for three months to prevent recurrence, and who is sitting in the neuromuscular clinic being told by his neurologist that the treatment for his condition is a supervised aerobic exercise program.

Each family is reacting logically to the evidence available to them. The 92 mg/dL bedtime glucose is a real measurement of a real normal glucose level at that moment. The hepatic improvement in GSD type III is a real improvement — the liver enzymes are genuinely trending down. The myoglobinuria episodes were genuinely triggered by exercise — the connection is real and the fear is warranted. What each family cannot construct from their available evidence is the mechanism that makes their intuitive response counterproductive. In GSD type I, the normal bedtime glucose does not reflect hepatic glucose reserve — it reflects cornstarch absorption, and without cornstarch the liver is metabolically incapable of maintaining glucose regardless of how full its glycogen stores appear on ultrasound. In GSD type IIIa, the hepatic improvement does not represent the whole disease — the debranching enzyme absence in cardiac and skeletal muscle is driving progressive cardiomyopathy and myopathy that the improving liver enzyme trend does not detect and that protein restriction would accelerate by removing the repair substrate the affected muscle depends on. In McArdle disease, the rhabdomyolysis episodes were not caused by exercise in general — they were caused by high-intensity anaerobic exercise that exceeded the aerobic energy supply; moderate aerobic exercise uses blood glucose and fatty acids that McArdle muscle can access normally, and the aerobic exercise program builds the oxidative capacity that raises the threshold at which muscle glycogen would be needed, while complete rest eliminates that threshold entirely.

The three conversations in this post take place in Houston, San Antonio, and Dallas — in the outpatient pediatric metabolic and neuromuscular clinics of children’s hospitals serving Spanish-speaking working-class Texas families. Each family arrived at their misunderstanding through a reasonable inference from their observations. The pediatric glycogen storage disorder nurse who can explain the biochemical mechanism specifically enough that the family understands why their intuition is wrong in this case — not just that it is wrong — is the clinician who prevents the treatment lapses and the management decisions that produce the crises these families are trying to avoid.

Scenario 1: Andrés Martínez-García — Houston, Texas

Pediatric metabolic nurse Lupe Cisneros-Vega and the parents who cannot understand how a bedtime glucose of 92 mg/dL became a 5 AM glucose of 14 mg/dL without any warning

Andrés is six years old. He lives in Houston with Rosa Martínez-López, thirty-three, a home health aide, and Javier García-Vega, thirty-seven, an HVAC technician. Andrés was diagnosed with GSD type I at age four months after presenting to the emergency department in Houston with lethargy, respiratory distress, and point-of-care glucose 26 mg/dL. Laboratory evaluation confirmed severe hypoglycemia alongside a metabolic picture consistent with GSD type I: serum lactate 4.2 mmol/L (normal <2.0), triglycerides 680 mg/dL (normal <150 in infants), uric acid 8.4 mg/dL (normal <5.0), and hepatomegaly with liver 6 cm below the costal margin on examination. Liver ultrasound showed markedly increased hepatic echogenicity from diffuse glycogen deposition. Molecular testing confirmed homozygous G6PC c.247C>T, p.Pro83Ser — a pathogenic GSD Ia mutation that abolishes glucose-6-phosphatase catalytic activity.

Andrés was started on uncooked cornstarch (UCCS) every three hours while awake from age six months. By eighteen months, the frequency of required overnight dosing and the difficulty of maintaining reliable three-hour overnight intervals led to gastrostomy tube placement for continuous overnight cornstarch delivery via a pump at 0.5 g/kg per hour from 10 PM to 6 AM. On this regimen, his metabolic markers normalized progressively: triglycerides fell from 680 to 285 mg/dL, uric acid normalized to 5.1 mg/dL, and lactate stabilized at 1.8 mmol/L on spot check. His height and weight trajectory, previously compromised by the early hypoglycemic episodes, normalized to the 45th percentile for age. Rosa and Javier had learned to maintain the overnight pump without interruption and had done so reliably for four years.

Six weeks before this clinic visit, Rosa checked Andrés’s glucose at 10 PM before starting the pump: 92 mg/dL. Andrés was sleeping comfortably and looked well. Rosa and Javier had a rare night off together and wanted to give Andrés an undisturbed sleep without the tube attached. They reasoned that 92 mg/dL was an excellent glucose level for a six-year-old, that Andrés had been doing so well for four years, and that one night without the pump was unlikely to cause harm. They planned to check his glucose at 6 AM. At 5 AM Javier went in for another reason and found Andrés unresponsive. The glucometer read 14 mg/dL. Emergency services were called; Andrés received intravenous dextrose in the ambulance and recovered fully in the emergency department. At today’s follow-up, both parents are visibly shaken and need to understand what happened.

Rosa: “Enfermera Cisneros-Vega, no entendemos qué pasó. A las diez de la noche, la glucosa era 92. Eso está perfectamente normal. Andrés se veía bien, dormía tranquilo. ¿Cómo es posible que a las cinco de la mañana tuviera 14? ¿En siete horas? Sin síntomas. No lloraba. No se movía. No sudaba. ¿Cómo puede estar bien a las diez y en peligro a las cinco si el número empezó tan alto?”

(Nurse Cisneros-Vega, we do not understand what happened. At ten at night, the glucose was 92. That is perfectly normal. Andrés looked well, sleeping calmly. How is it possible that at five in the morning he had 14? In seven hours? Without symptoms. He was not crying. He was not moving. He was not sweating. How can he be fine at ten and in danger at five if the number started so high?)

Javier: “Yo pensé que si la glucosa era 92 a las diez, en el peor de los casos a las cinco de la mañana sería como 60 o 70 — bajo pero no peligroso. ¿Por qué bajó tanto? ¿Y por qué no dio señales?”

(I thought that if the glucose was 92 at ten, in the worst case at five in the morning it would be around 60 or 70 — low but not dangerous. Why did it drop so much? And why did he show no signs?)

Nurse Lupe Cisneros-Vega recognizes that this family has followed the cornstarch regimen perfectly for four years, and that the incident occurred because of a gap between what the glucose meter reading means in a healthy child and what it means in a GSD type I child. She begins by answering the specific numerical question. “Voy a explicarles exactamente qué pasó, empezando por el número 92 de las diez de la noche. En un niño sin la enfermedad de almacenamiento de glucógeno, un número de 92 a las diez de la noche no significa que la glucosa va a estar arriba de 70 a las cinco de la mañana. Significa que el hígado tiene reservas de glucógeno disponibles y puede liberar glucosa al torrente sanguíneo toda la noche si baja el azúcar. En Andrés, ese número de 92 significa algo diferente. Significa que la maicena que le dieron en la tarde todavía estaba siendo absorbida a las diez. Eso es todo lo que significa. No significa que el hígado de Andrés tiene la capacidad de mantener la glucosa.”

(I am going to explain to you exactly what happened, starting with the number 92 at ten at night. In a child without glycogen storage disease, a number of 92 at ten at night does not mean the glucose will be above 70 at five in the morning. It means the liver has glycogen reserves available and can release glucose into the bloodstream all night if blood sugar drops. In Andrés, that number of 92 means something different. It means the cornstarch given in the afternoon was still being absorbed at ten. That is all it means. It does not mean Andrés’s liver has the capacity to maintain glucose.)

Rosa: “¿Por qué no puede mantener la glucosa si tiene glucógeno en el hígado?”

(Why can it not maintain glucose if it has glycogen in the liver?)

“Esa es exactamente la pregunta correcta. El hígado de Andrés tiene más glucógeno de lo normal — de hecho tiene tanto glucógeno que se puede ver en el ultrasonido como un tejido más blanco de lo normal. Pero ese glucógeno está atrapado. Para convertir el glucógeno en glucosa libre y mandarla a la sangre, el hígado necesita una enzima llamada glucosa-6-fosfatasa. El proceso funciona así: el glucógeno se rompe en un paso intermedio llamado glucosa-6-fosfato. Ese paso lo puede hacer el hígado de Andrés sin problema. Pero para pasar de glucosa-6-fosfato a glucosa libre — la glucosa que puede salir del hígado a la sangre — se necesita la glucosa-6-fosfatasa. La mutación en el gen G6PC de Andrés impide que su cuerpo fabrique esa enzima. Permanentemente. No por un tiempo. No mientras está enfermo. Permanentemente. El hígado de Andrés no puede producir esa enzima. Entonces cuando el glucógeno llega al paso de glucosa-6-fosfato, el proceso se detiene ahí. El glucógeno no se puede convertir en glucosa libre. El mismo problema existe con la gluconeogénesis — el proceso por el cual el hígado fabrica glucosa nueva a partir de lactato y aminoácidos cuando no hay glucógeno suficiente. Ese proceso también termina en glucosa-6-fosfato y necesita la misma enzima para producir glucosa libre. Sin glucosa-6-fosfatasa, ninguno de los dos procesos puede exportar glucosa al torrente sanguíneo.”

(That is exactly the right question. Andrés’s liver has more glycogen than normal — in fact it has so much glycogen that it can be seen on ultrasound as a tissue that is whiter than normal. But that glycogen is trapped. To convert glycogen to free glucose and send it to the blood, the liver needs an enzyme called glucose-6-phosphatase. The process works like this: glycogen is broken down to an intermediate step called glucose-6-phosphate. Andrés’s liver can do that step without a problem. But to go from glucose-6-phosphate to free glucose — the glucose that can leave the liver to the blood — glucose-6-phosphatase is needed. The mutation in Andrés’s G6PC gene prevents his body from making that enzyme. Permanently. Not temporarily. Not while he is sick. Permanently. Andrés’s liver cannot produce that enzyme. So when glycogen reaches the glucose-6-phosphate step, the process stops there. Glycogen cannot be converted to free glucose. The same problem exists with gluconeogenesis — the process by which the liver manufactures new glucose from lactate and amino acids when there is not enough glycogen. That process also ends at glucose-6-phosphate and needs the same enzyme to produce free glucose. Without glucose-6-phosphatase, neither process can export glucose to the bloodstream.)

Javier: “¿Entonces el hígado está lleno de glucógeno que no puede usar?”

(So the liver is full of glycogen it cannot use?)

“Exactamente. El hígado de Andrés está lleno de glucógeno atrapado. Cuando la glucosa de la maicena de la tarde se terminó de absorber — aproximadamente a medianoche o a la una de la mañana, dependiendo de cuándo fue la última dosis — la glucosa empezó a bajar. El hígado de Andrés, a diferencia del hígado de ustedes, no puede hacer nada. No puede liberar glucosa de su glucógeno. No puede fabricar glucosa nueva. La glucosa sigue bajando sin ningún mecanismo que la detenga. Por eso cuando llegaron a las cinco de la mañana, después de siete horas sin maicena, la glucosa era 14. El hígado estaba lleno de glucógeno y era completamente incapaz de usarlo.”

(Exactly. Andrés’s liver is full of trapped glycogen. When the glucose from the afternoon cornstarch finished being absorbed — approximately at midnight or one in the morning, depending on when the last dose was — glucose began falling. Andrés’s liver, unlike your liver, cannot do anything. It cannot release glucose from its glycogen. It cannot manufacture new glucose. Glucose keeps falling without any mechanism to stop it. That is why when you arrived at five in the morning, after seven hours without cornstarch, glucose was 14. The liver was full of glycogen and completely incapable of using it.)

Rosa: “¿Y por qué Andrés no lloraba? ¿Por qué no se movió?”

(And why was Andrés not crying? Why did he not move?)

“Esa es la parte más peligrosa de la enfermedad de Andrés. En un niño normal, cuando la glucosa baja a 60 o 70, el cuerpo libera adrenalina y otros signos de alarma — el niño suda, tiembla, llora, tiene hambre, despierta. Eso es el sistema de alarma del cuerpo. Andrés lleva toda su vida con episodios de hipoglucemia — desde los cuatro meses. El cuerpo humano, cuando está expuesto repetidamente a hipoglucemia, se adapta reduciendo la respuesta de alarma para conservar recursos. Esa adaptación es la más peligrosa de la GSD tipo I. Significa que Andrés puede estar con glucosa de 20, de 15, de 14 — sin sudar, sin llorar, sin moverse, sin ninguna señal visible. La hipoglucemia lo silencia en vez de despertarlo. Por eso no pueden confiar en los síntomas para saber si Andrés está en peligro. La única manera confiable de saber es el glucómetro. Y la única manera de evitar que llegue a esos números durante la noche es la bomba de maicena funcionando sin interrupción.”

(That is the most dangerous part of Andrés’s disease. In a normal child, when glucose falls to 60 or 70, the body releases adrenaline and other alarm signals — the child sweats, trembles, cries, is hungry, wakes up. That is the body’s alarm system. Andrés has had hypoglycemia episodes his entire life — since four months. The human body, when repeatedly exposed to hypoglycemia, adapts by reducing the alarm response to conserve resources. That adaptation is the most dangerous feature of GSD type I. It means Andrés can have glucose of 20, 15, 14 — without sweating, without crying, without moving, without any visible sign. The hypoglycemia silences him instead of waking him. That is why you cannot rely on symptoms to know whether Andrés is in danger. The only reliable way to know is the glucometer. And the only way to prevent his reaching those numbers overnight is the cornstarch pump running without interruption.)

Javier was quiet for a moment. “Entonces el 92 que vió Rosa — ese número era la maicena de la tarde, no la reserva del hígado. Cuando la maicena se terminó, no había nada más.”

(So the 92 Rosa saw — that number was the afternoon cornstarch, not the liver’s reserve. When the cornstarch ran out, there was nothing else.)

“Exactamente. El 92 era el nivel de glucosa mientras la maicena todavía se estaba absorbiendo. No era la capacidad del hígado. El hígado de Andrés estaba al lado de esa glucosa de 92, lleno de glucógeno, incapaz de contribuir un solo miligrama. Cuando la maicena se terminó, no había nada más. El 92 que vio Rosa a las diez de la noche era la señal de que la maicena estaba funcionando — no de que Andrés no la necesitaba.”

(Exactly. The 92 was the glucose level while the cornstarch was still being absorbed. It was not the liver’s capacity. Andrés’s liver was next to that glucose of 92, full of glycogen, incapable of contributing a single milligram. When the cornstarch ran out, there was nothing else. The 92 Rosa saw at ten at night was the sign that the cornstarch was working — not that Andrés did not need it.)

Rosa: “¿Y hay algún momento en que sea seguro no poner la bomba?”

(And is there ever a moment when it is safe not to use the pump?)

“No mientras la glucosa de Andrés dependa de la maicena. Las investigaciones en adultos con GSD tipo I muestran que algunos pacientes pueden tolerar períodos ligeramente más largos entre dosis cuando crecen — porque el músculo y el riñón pueden hacer algo de gluconeogénesis que el hígado no puede. Pero eso es en adultos con GSD tipo I bien controlada por años, y es una decisión que toma el médico con glucosa continua monitoreada. Andrés tiene seis años. La decisión de cambiar cualquier parte del régimen nocturno la tomamos juntos el equipo médico con monitoreo continuo de glucosa — nunca unilateralmente. Lo que ocurrió no fue un error de su parte — fue un malentendido comprensible sobre lo que significa ese número. Ahora que entienden qué mide el glucómetro en Andrés — la maicena, no el hígado — tienen la información que necesitan para entender por qué la bomba no es negociable.”

(Not while Andrés’s glucose depends on cornstarch. Research in adults with GSD type I shows that some patients can tolerate slightly longer periods between doses as they grow — because muscle and kidney can do some gluconeogenesis that the liver cannot. But that is in adults with GSD type I well controlled for years, and it is a decision made by the medical team with continuous glucose monitoring. Andrés is six years old. The decision to change any part of the overnight regimen is made together by the medical team with continuous glucose monitoring — never unilaterally. What happened was not an error on your part — it was a comprehensible misunderstanding about what that number means. Now that you understand what the glucometer measures in Andrés — the cornstarch, not the liver — you have the information you need to understand why the pump is not negotiable.)

Javier: “Entendemos. El 92 era evidencia de que la maicena funcionaba. No de que ya no la necesitaba.”

(We understand. The 92 was evidence that the cornstarch was working. Not that he no longer needed it.)

“Eso es exactamente correcto. Y eso es lo que quiero que recuerden cada vez que vean un número bueno en el glucómetro de Andrés. El número bueno es la maicena funcionando. La maicena tiene que seguir funcionando para que el número siga siendo bueno.”

(That is exactly right. And that is what I want you to remember every time you see a good number on Andrés’s glucometer. The good number is the cornstarch working. The cornstarch has to keep working for the number to keep being good.)

Six months after the incident, Andrés has a continuous glucose monitor placed alongside the gastrostomy tube regimen. Rosa and Javier watch the overnight CGM trace on their phones. They have not missed a single pump connection since the incident. “Ahora entendemos que el número en el glucómetro es como la aguja de gasolina mientras la bomba de gasolina está abierta. Si cierras la bomba, la aguja no baja inmediatamente — hay gasolina en el tubo. Pero cuando se termina, se termina. Y el motor de Andrés no tiene tanque de reserva.” (“Now we understand that the number on the glucometer is like the fuel gauge while the fuel pump is open. If you close the pump, the gauge does not fall immediately — there is fuel in the tube. But when it runs out, it runs out. And Andrés’s engine has no reserve tank.”)

Scenario 2: Camila Torres-Espinoza — San Antonio, Texas

Pediatric metabolic nurse Blanca Herrera-Fuentes and the parents who cannot understand why a liver disease requires high protein intake instead of restriction

Camila is ten years old. She lives in San Antonio with Carmen Torres-Reyes, thirty-six, a school cafeteria worker, and Eduardo Espinoza-Cruz, forty-two, a plumbing contractor. Camila was diagnosed with GSD type IIIa at age seven after her pediatrician found marked hepatomegaly — liver 8 cm below the costal margin — at a routine physical exam. Liver function testing confirmed AST 134 U/L and ALT 119 U/L (upper limit of normal approximately 35 U/L). Gamma-glutamyl transferase was mildly elevated at 52 U/L. Fasting glucose after an overnight fast was 64 mg/dL — below normal but not profoundly hypoglycemic, consistent with the mild fasting hypoglycemia characteristic of GSD III. Creatine kinase was 2,240 U/L — markedly elevated for a seven-year-old girl, indicating ongoing skeletal muscle cell membrane damage. Leukocyte AGL enzyme activity: 2% of normal. Molecular testing confirmed compound heterozygous AGL c.3965delT (frameshift) and c.4258-2A>G (splice site), both pathogenic. Liver biopsy showed diffuse glycogen accumulation in hepatocytes with early portal fibrosis graded F1 on the METAVIR scale. Echocardiogram at diagnosis: LV posterior wall thickness 9.2 mm — at the upper limit of normal for Camila’s body surface area — with trace mitral regurgitation. LV ejection fraction was 64%.

Over three years of dietary management — a high-carbohydrate diet in early childhood transitioning to a high-protein diet as she grew — Camila’s liver enzymes have improved substantially. AST is now 64 U/L and ALT 58 U/L. Her hepatomegaly has partially regressed; liver span is 13 cm. Her fasting glucose is 72 mg/dL — completely normal; she has had no hypoglycemic episodes in the past two years. Her CK remains elevated at 1,680 U/L. Her echocardiogram at the most recent annual surveillance: LV posterior wall thickness 9.8 mm — slightly increased from 9.2 mm at diagnosis, now definitively at the upper limit of normal for age and body surface area, with trace mitral regurgitation unchanged. Eduardo and Carmen have just received the dietitian’s updated recommendation: 3.5 g/kg per day of dietary protein, with emphasis on lean animal protein at every meal. In preparation for the clinic visit, Carmen spent an evening reading about liver disease dietary management online.

Carmen: “Enfermera Herrera-Fuentes, yo investigé en internet sobre dieta para enfermedad del hígado. Todo lo que encontré dice que la restricción de proteína es lo que se recomienda para el hígado. Que demasiada proteína produce amoníaco que el hígado dañado no puede procesar. Entonces no entiendo por qué la nutricionista nos está diciendo que aumentemos la proteína a 3.5 gramos por kilo. Las enzimas del hígado de Camila están mejorando — están bajando. ¿No debería ser el momento de reducir lo que trabajamos contra el hígado?”

(Nurse Herrera-Fuentes, I researched online about diet for liver disease. Everything I found says that protein restriction is what is recommended for the liver. That too much protein produces ammonia that the damaged liver cannot process. So I do not understand why the dietitian is telling us to increase protein to 3.5 grams per kilo. Camila’s liver enzymes are improving — they are falling. Should it not be the time to reduce what we work against the liver?)

Eduardo: “Y además, Camila nunca ha tenido una crisis de azúcar bajo. El azúcar está normal. Si el azúcar está normal y el hígado está mejorando, ¿no podemos reducir el tratamiento?”

(And besides, Camila has never had a low blood sugar episode. Blood sugar is normal. If blood sugar is normal and the liver is improving, can we not reduce treatment?)

Nurse Blanca Herrera-Fuentes understands that the family has done exactly what engaged parents do — they researched their child’s condition — and found information that is accurate for a different liver disease entirely. She begins by acknowledging both the research and the improvement. “Primero — la investigación que hizo está correcta para las enfermedades del hígado donde el hígado no puede procesar el amoníaco que viene de las proteínas. Esos son los trastornos del ciclo de la urea y la cirrosis terminal con encefalopatía hepática. En esas enfermedades, sí se restringe la proteína porque el hígado no puede neutralizar el amoníaco. Pero la enfermedad de Camila — la GSD tipo III — no es esas enfermedades. El hígado de Camila puede procesar el amoníaco normalmente. La restricción de proteína que encontró usted en internet no aplica a Camila.”

(First — the research you did is correct for liver diseases where the liver cannot process the ammonia that comes from proteins. Those are urea cycle disorders and end-stage cirrhosis with hepatic encephalopathy. In those diseases, yes, protein is restricted because the liver cannot neutralize the ammonia. But Camila’s disease — GSD type III — is not those diseases. Camila’s liver can process ammonia normally. The protein restriction you found online does not apply to Camila.)

Carmen: “¿Entonces por qué las enzimas del hígado están elevadas?”

(So why are the liver enzymes elevated?)

“Las enzimas del hígado en la GSD tipo III están elevadas porque las células del hígado están llenas de glucógeno — la enzima que falta no puede limpiar ese glucógeno en los lisosomas, y las células hepáticas que están bajo esa presión liberan enzimas hacia la sangre. Eso es lo que mide la AST y la ALT elevadas — el glucógeno, no el daño por proteína. Y esas enzimas están bajando porque el tratamiento está reduciendo la acumulación. Eso es una muy buena noticia. Lo que quiero explicarles es que el hígado es solamente una parte de la enfermedad de Camila — y que la parte del hígado está mejorando, pero hay otra parte que necesita seguimiento y que no mejora de la misma manera.”

(The liver enzymes in GSD type III are elevated because liver cells are full of glycogen — the missing enzyme cannot clear that glycogen in the lysosomes, and the liver cells under that pressure release enzymes into the blood. That is what elevated AST and ALT measure — glycogen, not protein damage. And those enzymes are falling because treatment is reducing the accumulation. That is very good news. What I want to explain to you is that the liver is only one part of Camila’s disease — and the liver part is improving, but there is another part that needs follow-up and that does not improve the same way.)

Eduardo: “¿Otra parte?”

(Another part?)

“La GSD tipo III en el tipo de Camila — el IIIa, que es el más común — afecta tanto el hígado como el músculo. La misma enzima que falta en el hígado, la enzima desramificante AGL, también está ausente en el músculo de Camila. En el músculo, el problema es diferente: el glucógeno se acumula en las fibras del músculo esquelético y en el músculo cardíaco. Esa acumulación en las fibras musculares produce un daño progresivo silencioso — los músculos van perdiendo su arquitectura normal a medida que el glucógeno se acumula año tras año. Hay dos señales de eso en Camila que están en el expediente de hoy. La primera es la CK — la creatinkinasa — que está en 1,680. La CK se eleva cuando las membranas de las células musculares se rompen. En Camila, la CK está elevada porque el glucógeno en el músculo está causando daño celular continuo, aunque ella no tenga dolor muscular todavía. La segunda señal está en el ecocardiograma. La pared posterior del ventrículo izquierdo mide 9.8 milímetros — un poco más gruesa que cuando fue diagnosticada a los siete años, cuando era 9.2. Eso es glucógeno acumulándose en el músculo cardíaco. No es síntoma todavía, pero es el signo temprano de la miocardiopatía que puede desarrollarse si el músculo cardíaco sigue acumulando glucógeno.”

(GSD type III in Camila’s type — IIIa, the most common — affects both liver and muscle. The same missing enzyme in the liver, the AGL debranching enzyme, is also absent in Camila’s muscle. In muscle, the problem is different: glycogen accumulates in skeletal muscle fibers and in cardiac muscle. That accumulation in muscle fibers produces silent progressive damage — muscles progressively lose their normal architecture as glycogen accumulates year after year. There are two signs of that in Camila that are in today’s file. The first is the CK — creatine kinase — which is at 1,680. CK rises when muscle cell membranes break down. In Camila, CK is elevated because glycogen in muscle is causing continuous cellular damage, even though she does not have muscle pain yet. The second sign is in the echocardiogram. The posterior wall of the left ventricle measures 9.8 millimeters — a bit thicker than when she was diagnosed at age seven, when it was 9.2. That is glycogen accumulating in cardiac muscle. It is not a symptom yet, but it is the early sign of the cardiomyopathy that can develop if cardiac muscle continues accumulating glycogen.)

Carmen: “¿Miocardiopatía? ¿Del corazón?”

(Cardiomyopathy? Of the heart?)

“Sí. La miocardiopatía en la GSD tipo IIIa es la complicación más seria a largo plazo — afecta a aproximadamente el treinta por ciento de los pacientes con este subtipo. En los años en que la acumulación de glucógeno en el músculo cardíaco es mayor, la pared del ventrículo izquierdo sigue engrosándose, la función cardiaca empieza a reducirse, y pueden aparecer arritmias. Por eso hacemos el ecocardiograma cada año aunque Camila no tenga síntomas cardíacos — para detectar el engrosamiento antes de que se convierta en disfunción. Ahora — ¿cómo entra la proteína en todo esto? La proteína ayuda de dos maneras. La primera: en la GSD tipo III, el hígado puede fabricar glucosa nueva a partir de aminoácidos — la gluconeogénesis — incluso cuando la enzima desramificante falta. El glucógeno no puede llegar completamente a glucosa, pero los aminoácidos como la alanina y la glutamina sí pueden convertirse en glucosa vía la gluconeogénesis, sin pasar por el paso donde la enzima falta. Una dieta alta en proteínas de alta calidad — pollo, huevo, pescado, carne — le da al hígado de Camila el material gluconeogénico que estabiliza la glucosa entre comidas, incluso mientras el glucógeno siga acumulándose. La segunda: la proteína es el material de construcción del músculo. El músculo esquelético y cardiaco de Camila está bajo estrés continuo por la acumulación de glucógeno. Para poder reparar el daño que el glucógeno está causando, las células musculares necesitan aminoácidos. Si reducimos la proteína, le quitamos al músculo el material que necesita para mantener su estructura contra ese daño continuo.”

(Yes. Cardiomyopathy in GSD type IIIa is the most serious long-term complication — it affects approximately thirty percent of patients with this subtype. In the years when glycogen accumulation in cardiac muscle is greatest, the left ventricular wall continues thickening, cardiac function begins declining, and arrhythmias can appear. That is why we do the echocardiogram every year even though Camila has no cardiac symptoms — to detect the thickening before it becomes dysfunction. Now — how does protein fit into all of this? Protein helps in two ways. The first: in GSD type III, the liver can make new glucose from amino acids — gluconeogenesis — even when the debranching enzyme is missing. Glycogen cannot fully reach glucose, but amino acids like alanine and glutamine can be converted to glucose via gluconeogenesis, without passing through the step where the enzyme is missing. A diet high in quality protein — chicken, eggs, fish, meat — gives Camila’s liver the gluconeogenic material that stabilizes glucose between meals, even while glycogen continues accumulating. The second: protein is the building material of muscle. Camila’s skeletal and cardiac muscle is under continuous stress from glycogen accumulation. To be able to repair the damage that glycogen is causing, muscle cells need amino acids. If we reduce protein, we remove from the muscle the material it needs to maintain its structure against that continuous damage.)

Eduardo: “Entonces la enfermedad del hígado está mejorando con el tratamiento. Pero hay una enfermedad del músculo, incluyendo el corazón, que necesita la proteína alta para proteger el músculo.”

(So the liver disease is improving with treatment. But there is a muscle disease, including the heart, that needs high protein to protect the muscle.)

“Exactamente. Son dos enfermedades en el mismo cuerpo de Camila. La enfermedad del hígado está respondiendo bien al tratamiento — las enzimas bajan y eso es real y es importante. La enfermedad del músculo no sigue el mismo camino que la del hígado. La CK elevada y el ecocardiograma nos dice que el músculo está bajo presión ahora mismo, aunque Camila no sienta nada todavía. Reducir la proteína haría peor la enfermedad del músculo aunque hiciera sentido para una enfermedad diferente del hígado. En la GSD tipo IIIa, la proteína alta no daña el hígado — el hígado de Camila puede procesar perfectamente bien el amoníaco que produce la proteína. Y el músculo de Camila necesita esa proteína para mantenerse.”

(Exactly. They are two diseases in the same body of Camila. The liver disease is responding well to treatment — enzymes are falling and that is real and important. The muscle disease does not follow the same path as the liver disease. The elevated CK and the echocardiogram tell us that muscle is under pressure right now, even though Camila does not feel anything yet. Reducing protein would worsen the muscle disease even though it would make sense for a different liver disease. In GSD type IIIa, high protein does not damage the liver — Camila’s liver can process the ammonia that protein produces perfectly well. And Camila’s muscle needs that protein to maintain itself.)

At the two-year follow-up on 3.5 g/kg/day protein, Camila’s CK has improved to 1,120 U/L. Her liver enzymes continue their downward trend: AST 42, ALT 38. Echocardiographic LV wall thickness is 9.9 mm — essentially stable from 9.8 mm. Carmen: “El equipo de nutrición tiene razón. Vemos que el músculo está mejorando en los números. El corazón está estable. Entendemos ahora que son dos enfermedades y la proteína es para la que no se ve.” (“The nutrition team is right. We see that the muscle is improving in the numbers. The heart is stable. We understand now that they are two diseases and the protein is for the one that is not visible.”)

Scenario 3: Diego Fuentes-Reyes — Dallas, Texas

Pediatric neuromuscular nurse Silvia Morales-Cruz and the parents who cannot understand why supervised exercise is the treatment when exercise caused the myoglobinuria

Diego is sixteen years old. He lives in Dallas with Ana Fuentes-López, forty-four, a dental office receptionist, and Carlos Reyes-Vásquez, forty-nine, a construction supervisor. Diego was diagnosed with McArdle disease (GSD type V) at age fifteen, three months before this clinic visit, following two episodes of myoglobinuria — dark brown urine — in the same month, both occurring after high-intensity soccer practice. In each episode, Diego developed severe muscle pain, weakness, and brown urine within one to two hours of practice ending; emergency department evaluation confirmed CK 34,000 U/L during the second episode, with normal renal function but myoglobinuria on urinalysis. He was admitted for intravenous hydration to prevent myoglobin-induced renal injury. The neurology team performed further evaluation: muscle biopsy confirmed absent myophosphorylase staining with subsarcolemmal glycogen accumulation. The forearm ischemic exercise test demonstrated the pathognomonic McArdle pattern — ammonia rose normally after forearm exercise (indicating the purine nucleotide cycle is intact and muscle is working anaerobically), but venous lactate did not rise (confirming that skeletal muscle glycogenolysis, which normally produces lactate, is absent). Molecular testing confirmed homozygous PYGM c.148C>T, p.Arg50Ter — the most common McArdle disease mutation in populations of European descent, producing a complete loss of myophosphorylase activity. Resting CK at diagnosis: 1,820 U/L, consistent with ongoing low-grade skeletal muscle membrane damage from glycogen accumulation even at rest.

Following diagnosis, Ana and Carlos were told that Diego should avoid high-intensity exercise and should not play soccer until the neurology team could evaluate him further. They heard the word “exercise caused this” and, over the next three months, prevented Diego from participating in physical education class, family walks, and any activity that might provoke muscle exertion. Diego went from a physically active teenager to a sedentary one who took the elevator instead of one flight of stairs. At today’s first full neuromuscular clinic visit, the metabolic neurologist has now prescribed a supervised aerobic exercise program at a specialized neuromuscular rehabilitation center: low-intensity aerobic activity at fifty percent of VO2 max for twenty minutes, three times per week, increasing by ten percent of duration every two weeks. Sucrose 30 grams by mouth fifteen minutes before each session. Ana and Carlos are confused and frightened by the recommendation.

Ana: “Enfermera Morales-Cruz, yo no entiendo. El doctor nos dice que Diego tiene que hacer ejercicio. Diego estuvo en el hospital con el músculo destruido por el ejercicio. Le dimos tres meses de descanso total para que los músculos se recuperaran. ¿Cómo puede ser que ahora el tratamiento sea más ejercicio? Parece que vamos a poner al mismo niño de vuelta en el hospital.”

(Nurse Morales-Cruz, I do not understand. The doctor tells us Diego has to exercise. Diego was in the hospital with his muscle destroyed by exercise. We gave him three months of complete rest so his muscles could recover. How can it be that now the treatment is more exercise? It seems like we are going to put the same boy back in the hospital.)

Carlos: “Yo trabajé en construcción veinte años. Sé que cuando un músculo se daña, necesita descanso para repararse. ¿Por qué una enfermedad muscular requiere más ejercicio?”

(I worked in construction for twenty years. I know that when a muscle is damaged, it needs rest to repair itself. Why does a muscle disease require more exercise?)

Nurse Silvia Morales-Cruz understands that this family has made a logical inference from an accurate premise — exercise caused the rhabdomyolysis — and generalized it incorrectly to all exercise. The key to the explanation is distinguishing between types of exercise, not defending exercise in general. She begins with the specific mechanism of the myoglobinuria episodes. “Lo que le pasó a Diego en los entrenamientos de fútbol no fue que el ejercicio dañó el músculo. Fue que un tipo específico de ejercicio — los sprints, los duelos explosivos, el esfuerzo anaeróbico intenso — llevó al músculo a una situación donde necesitaba energía más rápido de lo que el azúcar en sangre y las grasas podían darla. Déjenme explicar por qué eso es un problema específico para Diego que no es un problema para el ejercicio en general.”

(What happened to Diego in soccer training was not that exercise damaged the muscle. It was that a specific type of exercise — sprints, explosive duels, intense anaerobic effort — put the muscle in a situation where it needed energy faster than blood sugar and fats could supply it. Let me explain why that is a specific problem for Diego that is not a problem for exercise in general.)

Ana: “Por favor.”

(Please.)

“El músculo de Diego tiene dos fuentes principales de energía. La primera es la glucosa en la sangre y las grasas — que se procesan de forma aeróbica, con oxígeno, en las mitocondrias. Eso es el trabajo de las fibras musculares lentas, de resistencia. La segunda es el glucógeno dentro del músculo — que se puede procesar de forma anaeróbica, muy rápidamente, para esfuerzos explosivos o de alta intensidad. El glucógeno muscular es como la reserva de emergencia para cuando el azúcar y las grasas no llegan lo suficientemente rápido. La enzima de Diego — la miofosforilasa — es la enzima que activa ese glucógeno muscular. La mutación de Diego impide que su músculo produzca esa enzima permanentemente. Su músculo tiene todo el glucógeno disponible — incluso más de lo normal porque no se puede usar y se acumula — pero no puede activarlo porque la miofosforilasa no está. Cuando Diego hacía sprints y esfuerzo explosivo en el fútbol, el músculo necesitaba energía más rápido de lo que el azúcar y las grasas podían dar. Intentó activar el glucógeno. No pudo. La demanda de energía superó la oferta, el músculo tuvo una crisis energética, y las membranas de las células musculares se rompieron. La mioglobina — una proteína dentro de las células musculares — salió a la sangre y llegó al riñón como orina oscura.”

(Diego’s muscle has two main energy sources. The first is blood glucose and fats — which are processed aerobically, with oxygen, in the mitochondria. That is the work of slow, endurance muscle fibers. The second is glycogen inside the muscle — which can be processed anaerobically, very quickly, for explosive or high-intensity efforts. Muscle glycogen is like the emergency reserve for when sugar and fats do not arrive quickly enough. Diego’s enzyme — myophosphorylase — is the enzyme that activates that muscle glycogen. Diego’s mutation permanently prevents his muscle from producing that enzyme. His muscle has all the glycogen available — even more than normal because it cannot be used and accumulates — but it cannot activate it because myophosphorylase is absent. When Diego was doing sprints and explosive effort in soccer, the muscle needed energy faster than sugar and fats could deliver. It tried to activate the glycogen. It could not. Energy demand exceeded supply, the muscle had an energy crisis, and muscle cell membranes broke down. Myoglobin — a protein inside muscle cells — left into the blood and reached the kidney as dark urine.)

Carlos: “Entonces el problema es el ejercicio de alta intensidad — el que necesita la reserva de emergencia.”

(So the problem is high-intensity exercise — the kind that needs the emergency reserve.)

“Exactamente. El ejercicio aeróbico moderado — caminar a buen paso, ir en bicicleta a ritmo moderado, nadar despacio, trotar suavemente — usa principalmente el azúcar en sangre y las grasas. Esas vías no necesitan la miofosforilasa. Diego puede hacer ese tipo de ejercicio porque su músculo puede acceder a esa energía. Hay un fenómeno importante que Diego va a notar al empezar el programa. Los primeros ocho a diez minutos del ejercicio aeróbico moderado, Diego va a sentirse peor de lo que debería. El corazón irá más rápido, los músculos van a doler más de lo que esperaría por el nivel de esfuerzo. Eso es porque en los primeros minutos del ejercicio, el músculo intenta usar glucógeno además de azúcar y grasas — y el bloqueo de la miofosforilasa produce esa demanda sin respuesta. Eso se llama “muro” en la enfermedad de McArdle. Pero alrededor del minuto ocho o diez, algo cambia: el corazón se calma, el dolor del músculo disminuye, el ejercicio se hace más fácil de repente. A eso le llamamos el segundo aire. Ese es el momento en que los ácidos grasos circulantes se convierten en el combustible principal — el músculo dejó de intentar usar el glucógeno y cambió completamente a la combustión aeróbica de grasas. Después del segundo aire, Diego puede continuar el ejercicio moderado de forma cómoda y segura.”

(Exactly. Moderate aerobic exercise — walking at a good pace, cycling at moderate pace, swimming slowly, jogging gently — uses primarily blood sugar and fats. Those pathways do not need myophosphorylase. Diego can do that type of exercise because his muscle can access that energy. There is an important phenomenon Diego will notice when starting the program. The first eight to ten minutes of moderate aerobic exercise, Diego will feel worse than he should. The heart will go faster, the muscles will hurt more than would be expected for the effort level. That is because in the first minutes of exercise, the muscle tries to use glycogen in addition to sugar and fats — and the myophosphorylase block produces that demand without response. That is called the “wall” in McArdle disease. But around minute eight or ten, something changes: the heart calms, the muscle pain decreases, the exercise suddenly becomes easier. We call that the second wind. That is the moment when circulating fatty acids become the main fuel — the muscle stopped trying to use glycogen and switched completely to aerobic fat combustion. After the second wind, Diego can continue moderate exercise comfortably and safely.)

Ana: “¿Y el programa de ejercicio — por qué es el tratamiento?”

(And the exercise program — why is it the treatment?)

“Porque el ejercicio aeróbico entrena el músculo para depender más de las grasas y del azúcar — que son exactamente las vías que Diego puede usar. Cuando hacemos ejercicio aeróbico regular, las fibras musculares lentas desarrollan más mitocondrias y más enzimas oxidativas. Eso significa que pueden hacer más trabajo con el azúcar y las grasas antes de necesitar la reserva de emergencia del glucógeno. La intensidad a la que el glucógeno haría falta sube. Las actividades que antes empujaban a Diego al límite — las escaleras, el baile, la actividad familiar — quedan por debajo de ese límite. Hay un número en el expediente de Diego que muestra exactamente eso. Cuando fue diagnosticado hace tres meses, la CK en reposo era 1,820. Ese número refleja el daño muscular continuo de bajo nivel que ocurre incluso sin esfuerzo externo — solo del glucógeno acumulado en las fibras. En los últimos tres meses, Diego hizo el programa de ejercicio supervisado. En el control de hoy, la CK es 920. La CK bajó a la mitad en tres meses de ejercicio aeróbico. Eso es evidencia directa de que el ejercicio está reduciendo el daño muscular — no causándolo.”

(Because aerobic exercise trains the muscle to rely more on fats and sugar — which are exactly the pathways Diego can use. When we do regular aerobic exercise, slow muscle fibers develop more mitochondria and more oxidative enzymes. That means they can do more work with sugar and fats before needing the emergency glycogen reserve. The intensity at which glycogen would be needed rises. Activities that previously pushed Diego to the limit — stairs, dancing, family activity — fall below that limit. There is a number in Diego’s file that shows exactly that. When he was diagnosed three months ago, resting CK was 1,820. That number reflects the continuous low-level muscle damage that occurs even without external effort — just from the accumulated glycogen in the fibers. Over the past three months, Diego did the supervised exercise program. At today’s check, CK is 920. CK dropped by half in three months of aerobic exercise. That is direct evidence that exercise is reducing muscle damage — not causing it.)

Carlos was quiet, processing. “La CK bajó a la mitad. Eso es con ejercicio.”

(CK dropped by half. That is with exercise.)

“Con ejercicio aeróbico moderado supervisado, sí. Y ahora para la parte sobre el descanso. Ustedes le dieron a Diego tres meses de descanso total. Eso fue prudente en el período inmediato después de las crisis — el músculo necesitaba recuperarse de los episodios agudos. Pero el descanso a largo plazo tiene el efecto opuesto al que esperaban. Cuando el músculo no hace ejercicio aeróbico, pierde las mitocondrias y las enzimas oxidativas que construye con el ejercicio. La capacidad de usar las grasas como combustible cae. El umbral en el que el glucógeno haría falta también cae. Las actividades cotidianas — subir una escalera, cargar la mochila — empiezan a empujar a Diego hacia ese umbral. Un Diego que lleva tres meses sin ejercicio es más vulnerable a una crisis por una actividad normal de lo que era antes del descanso. Es exactamente lo contrario de lo que ustedes querían lograr. Por eso el programa de ejercicio aeróbico supervisado no es una opción — es la forma en que Diego tiene que vivir para mantenerse protegido.”

(With supervised moderate aerobic exercise, yes. And now for the part about rest. You gave Diego three months of complete rest. That was prudent in the immediate period after the crises — the muscle needed to recover from the acute episodes. But long-term rest has the opposite effect from what you expected. When muscle does not do aerobic exercise, it loses the mitochondria and oxidative enzymes it builds with exercise. The capacity to use fat as fuel falls. The threshold at which glycogen would be needed also falls. Daily activities — climbing a stair, carrying a backpack — start pushing Diego toward that threshold. A Diego who has gone three months without exercise is more vulnerable to a crisis from a normal activity than he was before the rest. That is exactly the opposite of what you wanted to achieve. That is why the supervised aerobic exercise program is not an option — it is the way Diego has to live to stay protected.)

Ana: “¿Y el fútbol?”

(And soccer?)

“Los sprints, los duelos uno a uno, los disparos al arco con esfuerzo máximo — eso sigue siendo el tipo de esfuerzo de alta intensidad que lleva al bloqueo de la miofosforilasa. Diego no puede hacer ese tipo de entrenamiento. Pero hay muchos atletas con enfermedad de McArdle que practican deportes en una versión adaptada — con caleñtamiento largo para llegar al segundo aire antes de entrar a la intensidad, con pausas cuando sienten que el muro se acerca, sin los sprints explosivos. Algunos juegan fútbol recreational de bajo ritmo. La conversación sobre cuánta actividad deportiva es segura para Diego específicamente la tendremos a medida que progrese en el programa y veamos cómo responde. Lo que sí puedo decirles es que el objetivo no es un Diego que no hace ejercicio — es un Diego cuyo músculo está tan bien entrenado aeróbicamente que puede hacer más de lo que podía antes.”

(Sprints, one-on-one duels, maximum-effort shots on goal — those remain the type of high-intensity effort that leads to the myophosphorylase block. Diego cannot do that type of training. But there are many athletes with McArdle disease who practice sports in an adapted version — with a long warmup to reach the second wind before entering intensity, with pauses when they feel the wall approaching, without explosive sprints. Some play low-pace recreational soccer. The conversation about how much sports activity is safe for Diego specifically we will have as he progresses in the program and we see how he responds. What I can tell you is that the goal is not a Diego who does not exercise — it is a Diego whose muscle is so well aerobically trained that he can do more than he could before.)

Carlos nodded slowly. “Entonces el descanso hace que las escaleras sean peligrosas. Y el ejercicio hace que las escaleras sean seguras.”

(So rest makes stairs dangerous. And exercise makes stairs safe.)

“En la enfermedad de McArdle, sí. La capacidad aeróbica de Diego es lo que lo protege. El ejercicio aeróbico moderado la construye. El descanso la destruye. Lo que le pasó a Diego en el fútbol no fue que el ejercicio sea peligroso para él. Fue que ese ejercicio específico fue demasiado intenso demasiado rápido sin el segundo aire. El programa que tiene ahora está diseñado para que Diego aprenda a encontrar el segundo aire y entrene en la zona donde está seguro.”

(In McArdle disease, yes. Diego’s aerobic capacity is what protects him. Moderate aerobic exercise builds it. Rest destroys it. What happened to Diego in soccer was not that exercise is dangerous for him. It was that that specific exercise was too intense too quickly without the second wind. The program he has now is designed for Diego to learn to find the second wind and train in the zone where he is safe.)

At the six-month follow-up, Diego’s CK is 680 U/L — the lowest it has been since diagnosis, approaching the upper limit of the normal reference range. His VO2 max has increased by 22% on the exercise program. He has had no episodes of myoglobinuria. He has returned to school physical education in the modified format, with a long warmup and no sprint components. Ana: “El segundo aire es real. Diego nos llama cuando lo encuentra — como a los nueve minutos de la caminata rápida. Dice que se siente como si cambiara una velocidad en el coche. Ahora entendemos que eso es el músculo cambiando al combustible que sí puede usar.” (“The second wind is real. Diego calls us when he finds it — around minute nine of the fast walk. He says it feels like shifting a gear in the car. We now understand that is the muscle shifting to the fuel it can actually use.”)